[HTML][HTML] COVID‐19 associated coagulopathy and thromboembolic disease: Commentary on an interim expert guidance
SC Cannegieter, FA Klok - Research and Practice in Thrombosis and …, 2020 - rpthjournal.org
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative
pathogen of a new infectious disease, coronavirus disease 2019 (COVID-19), that first …
pathogen of a new infectious disease, coronavirus disease 2019 (COVID-19), that first …
Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study
D Wichmann, JP Sperhake… - Annals of internal …, 2020 - acpjournals.org
Background: The new coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2), has caused more than 210 000 deaths worldwide. However, little is known about …
CoV-2), has caused more than 210 000 deaths worldwide. However, little is known about …
COVID-19 infection: viral macro-and micro-vascular coagulopathy and thromboembolism/prophylactic and therapeutic management
AS Manolis, TA Manolis, AA Manolis… - Journal of …, 2021 - journals.sagepub.com
Coronavirus-2019 (COVID-19) predisposes patients to arterial and venous thrombosis
commonly complicating the clinical course of hospitalized patients and attributed to the …
commonly complicating the clinical course of hospitalized patients and attributed to the …
COVID-19 and coagulative axis: review of emerging aspects in a novel disease
M Boccia, L Aronne, B Celia, G Mazzeo… - … Archives for Chest …, 2020 - monaldi-archives.org
Latest evidences from literature suggest that SARS-CoV-2 disease 2019 (COVID-19) is
commonly complicated with coagulopathy and that disseminated intravascular coagulation …
commonly complicated with coagulopathy and that disseminated intravascular coagulation …
High incidence of venous thromboembolic events in anticoagulated severe COVID‐19 patients
JF Llitjos, M Leclerc, C Chochois… - … of Thrombosis and …, 2020 - Wiley Online Library
Background Coagulopathy is a common abnormality in patients with COVID‐19. However,
the exact incidence of venous thromboembolic event is unknown in anticoagulated, severe …
the exact incidence of venous thromboembolic event is unknown in anticoagulated, severe …
Thrombosis in COVID‐19
Thrombotic complications are frequent in COVID‐19 and contribute significantly to mortality
and morbidity. We review several mechanisms of hypercoagulability in sepsis that may be …
and morbidity. We review several mechanisms of hypercoagulability in sepsis that may be …
Registry of arterial and venous thromboembolic complications in patients with COVID-19
Background Cardiovascular complications, including myocardial infarction, ischemic stroke,
and pulmonary embolism, represent an important source of adverse outcomes in …
and pulmonary embolism, represent an important source of adverse outcomes in …
Anticoagulation before hospitalization is a potential protective factor for COVID‐19: insight from a French multicenter cohort study
Background Coronavirus disease 2019 (COVID‐19) is a respiratory disease associated with
thrombotic outcomes with coagulation and endothelial disorders. Based on that, several …
thrombotic outcomes with coagulation and endothelial disorders. Based on that, several …
[HTML][HTML] Incidence of thrombotic complications in COVID-19: on behalf of ICODE: The International COVID-19 Thrombosis Biomarkers Colloquium
A high incidence of thrombosis in hospitalised patients with COVID-19 was identified early
during the pandemic. Accurately quantifying thrombotic risk may assist prognosis and guide …
during the pandemic. Accurately quantifying thrombotic risk may assist prognosis and guide …
D-dimer and death in critically ill patients with coronavirus disease 2019
OBJECTIVES: Hypercoagulability may be a key mechanism for acute organ injury and death
in patients with severe coronavirus disease 2019, but the relationship between elevated …
in patients with severe coronavirus disease 2019, but the relationship between elevated …